Clinical Trial Update: RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) [Phase 2]

View source ↗

Summary

A Phase 2 trial (QUADRUPLE THREAT) evaluated RRx-001 in small cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and epithelial ovarian cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Neuroendocrine Tumors
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• RRx-001

Snippet

Sponsor: EpicentRx, Inc. | Conditions: Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2025-03-17